NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.43
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.33

30 Nov
2023

0.040

OPEN

$4.38

0.93%

HIGH

$4.41

788,367

LOW

$4.31

TARGET
$4.518 4.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 6.6 5.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 100.0% - 22.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 79.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 0.0% 0.0% xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx6.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx167.5 M
Book Value Per Share xxxxxxxxxxxxxxx54.2
Net Operating Cash Flow xxxxxxxxxxxxxxx23.3 M
Net Profit Margin xxxxxxxxxxxxxxx11.87 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx13.14 %
Return on Invested Capital xxxxxxxxxxxxxxx12.44 %
Return on Assets xxxxxxxxxxxxxxx9.47 %
Return on Equity xxxxxxxxxxxxxxx13.14 %
Return on Total Capital xxxxxxxxxxxxxxx11.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx19.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx8 M
Total Debt xxxxxxxxxxxxxxx11 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx112 M
Price To Book Value xxxxxxxxxxxxxxx8.75

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx3.6 M
Capex % of Sales xxxxxxxxxxxxxxx2.13 %
Cost of Goods Sold xxxxxxxxxxxxxxx42 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx108 M
Research & Development xxxxxxxxxxxxxxx27 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

23/08/2023

5

Sell

$3.90

-9.93%

FY23 net profit was ahead of estimates while revenue was in line. Citi notes the Nanosonics installed base grew at the slowest rate in eight years with the company flagging some Trophon orders were delayed because of constrained hospital budgets.

The Coris launch has been pushed out with an FDA application expected to be submitted in the third quarter of FY24. Citi revises EBIT estimates for FY24 and FY25 down by -4% and -36%, respectively. Sell rating retained. Target is reduced to $3.90 from $4.20.

FORECAST
Citi forecasts a full year FY24 dividend of 0.00 cents and EPS of 5.30 cents.
Citi forecasts a full year FY25 dividend of 0.00 cents and EPS of 6.40 cents.

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

NAN STOCK CHART

FNArena News on NAN

1
Australian Broker Call *Extra* Edition – Nov 15, 2023

Nov 15 2023 - Daily Market Reports
2
ESG Focus: Day Of The TRIFRS

Nov 09 2023 - ESG Focus
3
Rudi’s View: A Market Of Contradictions

Nov 01 2023 - Rudi's View
4
Rudi’s View: Outlook Negative, With Plenty Of Silver Linings

Sep 06 2023 - Rudi's View
5
Weekly Ratings, Targets, Forecast Changes – 25-08-23

Aug 28 2023 - Weekly Reports

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest